Update Focus Interpretation：CANMAT/ISBD 2018 Guidelines for the Management of Patients with Bipolar Disorders

doi:10.12114/j.issn.1007-9572.2018.00.408

Abstract

Abstract: With the development of society and the increase of priority given to mental health，the impact on patients caused by bipolar disorders is brought into focus. How to make a correct diagnosis and treatment is a big challenge to every psychiatrist. In this review，key content and changes for the CANMAT/ISBD 2018 guidelines for the management of patients with bipolar disorders are addressed. The main contents include the general highlights of the guidelines，the basis of bipolar disorders management，drug treatment and the role and recommendation of psychosocial intervention，hoping to give a hand to clinicians to better understand the new guidelines.

Key words: Bipolar disorder, Diagnosis, Treatment, Chronic disease management, Depressive episode, Manic episode, Hypomanic episode

摘要： 随着社会的发展和对精神卫生的重视，双相障碍对患者的影响越来越受到社会关注。如何做到正确诊断和合理治疗是每个临床医生所面对的重大难题。本文对《2018版加拿大抑郁和焦虑治疗网络/国际双相障碍学会双相障碍管理指南》重点内容进行分析解读，主要内容包括指南总体亮点、疾病管理基础、药物治疗、心理社会干预的作用和推荐，以期为广大临床工作者提供新的指导方针。

关键词: 双相情感障碍, 诊断, 治疗, 慢病管理, 抑郁发作, 躁狂发作, 轻躁狂发作

CHEN Jun,FANG Yiru,XU Yifeng. Update Focus Interpretation：CANMAT/ISBD 2018 Guidelines for the Management of Patients with Bipolar Disorders　[J]. Chinese General Practice, 2019, 22(2): 123-127. DOI: 10.12114/j.issn.1007-9572.2018.00.408.
陈俊,方贻儒,徐一峰. 《2018版加拿大抑郁和焦虑治疗网络/国际双相障碍学会双相障碍管理指南》的更新重点解读[J]. 中国全科医学, 2019, 22(2): 123-127. DOI: 10.12114/j.issn.1007-9572.2018.00.408.

References

［1］YATHAM L N，KENNEDY S H，O'DONOVAN C，et al．Canadian Network for Mood and Anxiety Treatments（CANMAT）guidelines for the management of patients with bipolar disorder：consensus and controversies［J］．Bipolar Disord，2005，7（Suppl 3）：5-69．DOI：10.1111/j.1399-5618.2005.00219.x.
［2］YATHAM L N，KENNEDY S H，O'DONOVAN C，et al．Canadian Network for Mood and Anxiety Treatments（CANMAT）guidelines for the management of patients with bipolar disorder：update 2007［J］．Bipolar Disord，2006，8（6）：721-739．DOI：10.1111/j.1399-5618.2006.00432.x.
［3］YATHAM L N，KENNEDY S H，SCHAFFER A，et al．Canadian Network for Mood and Anxiety Treatments（CANMAT）and International Society for Bipolar Disorders（ISBD）collaborative update of CANMAT guidelines for the management of patients with bipolar disorder：update 2009［J］．Bipolar Disord，2009，11（3）：225-255．DOI：10.1111/j.1399-5618.2009.00672.x.
［4］YATHAM L N，KENNEDY S H，PARIKH S V，et al．Canadian Network for Mood and Anxiety Treatments（CANMAT）and International Society for Bipolar Disorders（ISBD）collaborative update of CANMAT guidelines for the management of patients with bipolar disorder：update 2013［J］．Bipolar Disord，2013，15（1）：1-44．DOI：10.1111/bdi.12025.
［5］YATHAM L N，KENNEDY S H，PARIKH S V，et al．Canadian Network for Mood and Anxiety Treatments（CANMAT）and International Society for Bipolar Disorders（ISBD）2018 guidelines for the management of patients with bipolar disorder［J］．Bipolar Disord，2018，20（2）：97-170．DOI：10.1111/bdi.12609
［6］American Psychiatric Association，DSM-5 Task Force.Diagnostic and statistical manual of mental disorders：DSM-5?（5th ed.）［M］．Arlington：American Psychiatric Publishing，2013.
［7］FERRARI A J，CHARLSON F J，NORMAN R E，et al．Burden of depressive disorders by country，sex，age，and year：findings from the global burden of disease study 2010［J］．PLoS Med，2013，10（11）：e1001547．DOI：10.1371/journal.pmed.1001547.
［8］MERIKANGAS K R，AKISKAL H S，ANGST J，et al．Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication［J］．Arch Gen Psychiatry，2007，64（5）：543-552．DOI：10.1001/archpsyc.64.5.543.
［9］SCHAFFER A，ISOMETSA E T，TONDO L，et al．Epidemiology，neurobiology and pharmacological interventions related to suicide deaths and suicide attempts in bipolar disorder：part Ⅰ of a report of the International Society for Bipolar Disorders Task Force on Suicide in Bipolar Disorder［J］．Aust N Z J Psychiatry，2015，49（9）：785-802．DOI：10.1177/0004867415594427.
［10］MARANGELL L B，BAUER M S，DENNEHY E B，et al．Prospective predictors of suicide and suicide attempts in 1，556 patients with bipolar disorders followed for up to 2 years［J］．Bipolar Disord，2006，8（5 Pt 2）：566-575．DOI：10.1111/j.1399-5618.2006.00369.x.
［11］SMITH K A，CIPRIANI A.Lithium and suicide in mood disorders：updated meta-review of the scientific literature［J］．Bipolar Disord，2017，19（7）：575-586．DOI：10.1111/bdi.12543.
［12］WAGNER E H.Chronic disease management：what will it take to improve care for chronic illness?［J］．Eff Clin Pract，1998，1（1）：2-4.
［13］MICHALAK E E，MURRAY G，Collaborative Research Team to Study Psychosocial Issues in Bipolar Disorder（CREST.BD）．Development of the QoL.BD：a disorder-specific scale to assess quality of life in bipolar disorder［J］．Bipolar Disord，2010，12（7）：727-740．DOI：10.1111/j.1399-5618.2010.00865.x.
［14］DURGAM S，EARLEY W，LU K，et al．Global improvement with cariprazine in the treatment of bipolar Ⅰ disorder and schizophrenia：a pooled post hoc analysis［J］．Int J Clin Pract，2017，71（12）．DOI：10.1111/ijcp.13037.
［15］MORA E，PORTELLA M J，FORCADA I，et al．Persistence of cognitive impairment and its negative impact on psychosocial functioning in lithium-treated，euthymic bipolar patients：a 6-year follow-up study［J］．Psychol Med，2012，43（6）：1-10．DOI：10.1017/S0033291712001948.
［16］KOZICKY J M，TORRES I J，BOND D J，et al．Comparison of neuropsychological effects of adjunctive risperidone or quetiapine in euthymic patients with bipolar Ⅰ disorder［J］．Int Clin Psychopharmacol，2012，27（2）：91-99．DOI：10.1097/YIC.0b013e32834e3bea.
［17］PACCHIAROTTI I，BOND D J，BALDESSARINI R J，et al．The International Society for Bipolar Disorders（ISBD）task force report on antidepressant use in bipolar disorders［J］．Am J Psychiatry，2013，170（11）：1249-1262．DOI：10.1176/appi.ajp.2013.13020185.
［18］MCGIRR A，VOHRINGER P A，GHAEMI S N，et al．Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression：a systematic review and meta-analysis of randomised placebo-controlled trials［J］．Lancet Psychiatry，2016，3（12）：1138-1146．DOI：10.1016/S2215-0366（16）30264-4.
［19］于欣，方贻儒.中国双相障碍防治指南（第二版）［M］．北京：中华医学电子音像出版社，2015.
YU X，FANG Y R.Guidelines for the prevention and treatment of bipolar disorder in China（2nd edition）［M］．Beijing：Chinese Medical Multimedia Press，2015.
［20］REINARES M，SANCHEZ-MORENO J，FOUNTOULAKIS K N.Psychosocial interventions in bipolar disorder：what，for whom，and when［J］．J Affect Disord，2014，156：46-55．DOI：10.1016/j.jad.2013.12.017.
［21］GONZáLEZ ISASI A，ECHEBURúA E，LIMI?ANA J M，et al．Psychoeducation and cognitive-behavioral therapy for patients with refractory bipolar disorder：a 5-year controlled clinical trial［J］．Eur Psychiatry，2014，29（3）：134-141．DOI：10.1016/j.eurpsy.2012.11.002.
［22］MIKLOWITZ D J，OTTO M W，FRANK E，et al．Intensive psychosocial intervention enhances functioning in patients with bipolar depression：results from a 9-month randomized controlled trial［J］．Am J Psychiatry，2007，164（9）：1340-1347．DOI：10.1176/appi.ajp.2007.07020311.
［23］SCOTT J，PAYKEL E，MORRISS R，et al．Cognitive-behavioural therapy for severe and recurrent bipolar disorders：randomised controlled trial［J］．Br J Psychiatry，2006，188：313-320．DOI：10.1192/bjp.188.4.313.
［24］LAM D H，WATKINS E R，HAYWARD P，et al．A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder：outcome of the first year［J］．Arch Gen Psychiatry，2003，60（2）：145-152.
［25］MIKLOWITZ D J，CHUNG B.Family-focused therapy for bipolar disorder：reflections on 30 years of research［J］．Fam Process，2016，55（3）：483-499．DOI：10.1111/famp.12237.

[1]	HAN Leyang, ZHENG Huixian, TIAN Yiran, TANG Haoqing, LONG Ren, LI Daihan, LIU Xiaoyun. Measuring Integrated Services for Rural Chronic Disease Patients Based on Formative Measurement Theory [J]. Chinese General Practice, 2026, 29(31): 4543-4550.
[2]	KUANG Li, DING Xinxin, MA Yuanzhu. Application of Motivational Interviewing in Healthcare Provider-Patient Communication for Chronic Disease Management in Primary Care: from Principles to Practice [J]. Chinese General Practice, 2026, 29(31): 4536-4542.
[3]	LI Xiling, ZHANG Fan, YANG Xinyue, YANG Heng. Application of Exercise Snacks in Chronic Disease Management: a Scoping Review [J]. Chinese General Practice, 2026, 29(30): 4472-4479.
[4]	WEI Qiushi. Key Advances in the Collapse Assessment and Hip-preserving Treatment of Nontraumatic Osteonecrosis of the Femoral Head [J]. Chinese General Practice, 2026, 29(30): 4379-4389.
[5]	YE Ziqi, ZHOU Yujun, LIU Liu, ZHANG Yanfang, HONG Yun, RAO Yuefeng. Comprehensive Evaluation of ALK Inhibitors in the First-line Treatment of Patients with ALK-positive Non-small Cell Lung Cancer [J]. Chinese General Practice, 2026, 29(29): 4258-4264.
[6]	LI Zhixin, LIU Xiaoyu. Practical Research on Promoting Hierarchical Diagnosis and Treatment Through Collaborative Governance of Medical Quality in Regional Medical Alliance [J]. Chinese General Practice, 2026, 29(28): 4107-4116.
[7]	ZHANG Han, CAI Genshen, FENG Zhengwen, ZHANG Kaiyue, LIAN Dongbo, ZHANG Hua, ZHANG Jing. Evaluating the Availability of Health Services for Obesity Comorbidities under Hierarchical Diagnosis and Treatment in Beijing: a Healthcare Institution Survey Study [J]. Chinese General Practice, 2026, 29(28): 4117-4124.
[8]	FENG Yachen, LIU Lewei, XUE Jinyue, SUN Xianlin, LIU Huanzhong. Research Progress of Wearable Technology in the Diagnosis and Treatment of Mental Disorders [J]. Chinese General Practice, 2026, 29(27): 4016-4025.
[9]	WU Yuqiong, CHU Xiangling, HUANG Youye, SUN Li, JIANG Tian, ZHANG Qiu, HU Honglin. A Case Report and Literature Review of Hepatocyte Nuclear Factor 4α Gene Mutation Leading to Maturity-onset Diabetes of the Young [J]. Chinese General Practice, 2026, 29(27): 4011-4015.
[10]	HE Guoshu, REN Jingjing, ZHU Jiahong, MA Fanghui, SUN Wenping, LIU Lei, YIN Ankang, TANG Wenjuan. A Comparative Study of the Regional Characteristics of General Medically Unspecified Disease Patients in Northern and Southern China Based on Multi-center Real-world Data [J]. Chinese General Practice, 2026, 29(26): 3745-3751.
[11]	WANG Shuangrui, WANG Yongjia, FAN Xiaomin, LIU Xiangyu, HU Shunqing, YANG Zijian, ZHANG Xinjian. Efficacy and Safety of High-frequency Versus Low-frequency Stellate Ganglion Block Combined with Cognitive Behavioral Therapy for Insomnia in the Treatment of Insomnia Disorder [J]. Chinese General Practice, 2026, 29(25): 3678-3685.
[12]	WANG Yi, CHEN Yujie, LI Yao, YANG Linglin, LI Yong, HE Qinze, YUAN Quan. Effect of Eszopiclone and Telemedicine Management on NPPV Adherence in Patients with Coexisting Insomnia and Obstructive Sleep Apnea [J]. Chinese General Practice, 2026, 29(25): 3686-3693.
[13]	XUE Cuirong, WEI Wei, WU Renyuan, XUE Yaqin, XU Huijiang, LYU Weijiang, JIANG Dandan. Prevalence and Management Status of Chronic Kidney Disease in Hypertensive and Type 2 Diabetic Populations: a Community-based Cross-sectional Study [J]. Chinese General Practice, 2026, 29(25): 3650-3654.
[14]	LIU Yahui, XU Yanan, YUAN Ling, WU Ligui, ZHOU Yujie, KANG Yubiao. A Scoping Review on Triage for Palliative Care Patients Based on Priority Decision-making [J]. Chinese General Practice, 2026, 29(24): 3538-3544.
[15]	QI Jing, CAI Qing, ZHANG Wanting, GU Yan. A WeChat Mini-program-based Telerehabilitation Program for Stable COPD: Multidimensional Efficacy and Adherence Study [J]. Chinese General Practice, 2026, 29(24): 3476-3485.